| Literature DB >> 32912928 |
Xiao Chen1, Wei Liu1, Lu Wang1,2, Dafeng Lin3, Lulin Nie1, Kaiwu He1, Zhiwei Guo4, Feiqi Zhu5, Wenting Feng3, Weimin Liu6, Jing Yuan2,7, Xifei Yang1, Peter Spencer8, Jianjun Liu9.
Abstract
INTRODUCTION: Progressive distal symmetrical axonal neuropathy, a complication of diabetes mellitus (DM), has an unknown cause. Normal physiological metabolism and diabetic dysmetabolism are associated with the generation of γ-diketones. γ-Diketones form pyrroles with protein amines, notably with axonal proteins required for the maintenance of nerve fiber integrity, especially elongate, large-diameter peripheral nerve fibers innervating the extremities. We tested the hypothesis that neuropathy-associated γ-diketone pyrroles are elevated in DM. RESEARCH DESIGN AND METHODS: We measured the urinary concentration of γ-diketone pyrroles in age-matched and gender-matched elderly (60-84 years) persons with (n=267) or without (n=267) indicators of DM based in a community population (9411 community older adults aged ≥60 years) in Shenzhen city, Guangdong, China. We used statistical methods, including a generalized linear model, multivariate logistic regression analysis and restricted cubic splines, to assess linear and nonlinear relationships between urinary γ-diketone pyrroles and indicators of DM.Entities:
Keywords: diabetic ketoacidosis; diabetic neuropathies; metabolism
Mesh:
Substances:
Year: 2020 PMID: 32912928 PMCID: PMC7484872 DOI: 10.1136/bmjdrc-2020-001575
Source DB: PubMed Journal: BMJ Open Diabetes Res Care ISSN: 2052-4897
Figure 1Subject selection. HbA1c, glycated hemoglobin A1c.
Descriptive statistics of the study population
| Healthy control | Diabetes mellitus | P value | |
| Number of participants (F/M) | 267 (138/129) | 267 (138/129) | 1.000* |
| Age of participants (years) | 68.3±4.9 | 68.3±4.9 | 1.000* |
| Disease duration | – | 13.0±8.4 | – |
| Taking glucose-lowering agent (N) | – | 255 | – |
| Taking insulin (N) | – | 42 | – |
| Fasting blood glucose (mM) | 5.4 (0.7) | 8.9 (2.5) | <0.0001† |
| HbA1c (%) | 5.9 (0.5) | 7.8 (1.9) | <0.0001† |
| Urinary ketone bodies | 267 (265/2/0) | 252/13/2 | 0.002* |
| Urobilinogen | 267 (265/0/1/1) | 267 (265/1/1/0) | 1.000* |
| Occupational exposure to organic solvent (N/Y) | 267 (259/8) | 267 (261/6) | 0.788 |
| Smoking (never/former and current) | 266 (204/62) | 267 (202/65) | 0.839* |
| BMI (<24 kg/m2/=24 kg/m2/>24 kg/m2) | 265 (136/107/22) | 266 (119/105/42) | 0.024* |
| Hypertension (negative/positive) | 267 (122/145) | 267 (86/181) | 0.002* |
| Coronary disease (negative/positive) | 267 (156/11) | 263 (236/27) | 0.007* |
| Pyrrole adduct (μM) | 5.9 (4.3) | 7.5 (5.4) | <0.0001† |
*Differences between groups were examined by the χ2 test.
†Differences between groups were examined by Mann-Whitney U test.
BMI, body mass index; HbA1c, glycated hemoglobin A1c.
Figure 2Violin plot of the distribution of pyrrole adducts. The thick black bar in the center represents the IQR and the white dot in the middle represents the median value. The thin black line extended from the thick black bar represents the upper (max) and lower (min) adjacent values of the data.
Concentration of pyrrole adduct in urine samples
| Healthy control | Diabetes mellitus | ||
| Geometric mean (μM) | 5.5 | 7.2 | |
| Kurtosis | 1.8 | 8.4 | |
| Skewness | 0.9 | 2.2 | |
| Percentile (μM) | 25 | 3.9 | 5.1 |
| 50 | 5.9 | 7.5 | |
| 75 | 8.2 | 10.5 | |
| Maximum (μM) | 20.5 | 42.6 | |
Multiple linear regression analysis of independent predictors of pyrrole
| Β | SE | P value | Adjust R2 | |
| Univariate analysis | ||||
| Age | 0.021 | 0.041 | 0.633 | −0.001 |
| Gender | −0.159 | 0.395 | <0.0001 | 0.024 |
| Diabetes mellitus | 0.252 | 2.318 | <0.0001 | 0.062 |
| Fasting blood glucose | 0.167 | 0.071 | <0.0001 | 0.026 |
| HbA1c | 0.172 | 0.117 | <0.0001 | 0.028 |
| Urinary ketone bodies | 0.074 | 0.974 | 0.088 | 0.004 |
| Multivariate analysis | ||||
| Diabetes mellitus* | 0.265 | 0.392 | <0.0001 | 0.107 |
| Fasting blood glucose* | 0.169 | 0.073 | <0.0001 | 0.067 |
| HbA1c* | 0.168 | 0.120 | <0.0001 | 0.067 |
*Adjusted by age, gender, smoking status, BMI, hypertension, and coronary disease.
BMI, body mass index; HbA1c, glycated hemoglobin A1c.
Figure 3The restricted cubic spline for associations between indices of diabetes and concentration of pyrrole adducts. Dose-response curve between log-transformed fasting blood glucose and concentration of pyrrole adducts in the overall study population (A), male only (B) and female only (C). Dose-response curve between log-transformed glycated hemoglobin A1c (HbA1c) and concentration of pyrrole adducts in the overall population (D), male only (E) and female only (F). The lines represent adjusted ORs (solid lines) and 95% CIs (long dashed lines). The reference values were set at 5th percentiles, and the knots were set at 20th, 5th, 50th and 95th percentiles of the log-transformed concentrations, respectively. Adjusted factors were consistent with the multivariate analysis of multiple linear regression analysis. FBG, fasting blood glucose.